- Hormone replacement therapy (HRT) tablets, used to manage hormone deficiencies and imbalances such as menopause, hypothyroidism, male hypogonadism, and growth hormone deficiency, are becoming increasingly essential in improving patient quality of life and managing chronic endocrine disorders globally
- The rising prevalence of hormone-related conditions, growing awareness about HRT benefits, and advancements in pharmaceutical formulations that enhance safety and efficacy are key drivers boosting the demand for HRT tablets worldwide
- North America leads the HRT tablets market with the largest revenue share of approximately 38.5 % in 2025, driven by a high prevalence of menopausal and hypothyroid patients, well-established healthcare infrastructure, high healthcare spending, and widespread adoption of hormone therapies. The U.S. is witnessing notable growth due to increasing geriatric populations and ongoing clinical innovations
- The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, fueled by expanding healthcare access, rising awareness of hormone replacement options, improving healthcare infrastructure, and increasing prevalence of endocrine disorders in emerging economies such as China and India
- Menopause segment is expected to dominate the HRT tablets market with a market share of over 45% in 2025, due to its extensive prevalence among women worldwide and the growing demand for effective management of menopausal symptoms such as hot flashes, osteoporosis, and hormonal imbalances. The rising awareness about hormone replacement therapy benefits and increasing healthcare accessibility further support the segment’s growth
